<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01536353</url>
  </required_header>
  <id_info>
    <org_study_id>1110-AGSAV-P1</org_study_id>
    <nct_id>NCT01536353</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Evaluate the Bioavailability and Safety of AGSAV301</brief_title>
  <official_title>A Single Dose, Randomized, Open-label, 2x2 Crossover Study to Evaluate the Bioavailability and Safety of AGSAV301 Tablet in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ahn-Gook Pharmaceuticals Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ahn-Gook Pharmaceuticals Co.,Ltd</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the bioavailability and safety of AGSAV301 tablet in&#xD;
      healthy male volunteers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under Curve (AUC)</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10 ,12, 16, 24, 36, 48, 72, 96, 120, 168 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10 ,12, 16, 24, 36, 48, 72, 96, 120,168 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC (inf)</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10 ,12, 16, 24, 36, 48, 72, 96, 120,168 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10 ,12, 16, 24, 36, 48, 72, 96, 120, 168 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t(1/2β)</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10 ,12, 16, 24, 36, 48, 72, 96, 120, 168 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>AGSAV301</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Exforge 10/160</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AGSAV301</intervention_name>
    <description>tablet, q.d.</description>
    <arm_group_label>AGSAV301</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exforge 10/160</intervention_name>
    <description>Tablet, q.d.</description>
    <arm_group_label>Exforge 10/160</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult males 20 to 40 years at screening.&#xD;
&#xD;
          -  body weight ≥ 45kg and within ± 20% of the ideal body weight : Ideal body weight =&#xD;
             (height [cm] - 100) x 0.9&#xD;
&#xD;
          -  Be able to collect blood for study and visit for follow-up period&#xD;
&#xD;
          -  Subject who agrees to participate in this study and give written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have history of significant hepatic, renal, gastrointestinal, pulmonary,&#xD;
             musculoskeletal, endocrine, neuropsychiatric, hematologic, cardiovascular diseases&#xD;
&#xD;
          -  Have a gastrointestinal disease(ex : Crohn's disease, gastrointestinal ulcer)or&#xD;
             surgery(except for Appendectomy, Hernia repair) affected the absorption of medications&#xD;
&#xD;
          -  Inappropriate in Screening test (interview, vital sigh, BP, 12-lead ECG, laboratory&#xD;
             test etc.)&#xD;
&#xD;
          -  Hypersensitivity reactions to drugs or clinically significant hypersensitivity&#xD;
             reactions in the history of amlodipine or valsartan&#xD;
&#xD;
          -  drug abuse, or have a history of drug abuse showed a positive for the screening test&#xD;
             on urine : amphetamine, barbiturate, cocaine, opiates, benzodiazepines, cannabinoids,&#xD;
             methadone etc.&#xD;
&#xD;
          -  Subject who takes herbal medicine within 30 days, ethical drug within 14 days, OTC&#xD;
             within 7 days before the beginning of administration of investigational drug&#xD;
&#xD;
          -  Unusual diet affected the absorption, distribution, metabolism, excretion of&#xD;
             medications&#xD;
&#xD;
          -  Subject who treated with any investigational drugs within 60 days before the&#xD;
             administration of investigational drug&#xD;
&#xD;
          -  Previously donate whole blood within 60 days or component blood within 30 days or&#xD;
             transfusion within 30 days&#xD;
&#xD;
          -  Subject who takes inhibitors and inducers of drug metabolizing enzyme (Barbiturates&#xD;
             etc.) within 30days&#xD;
&#xD;
          -  Subject who have taken habitually caffeine (caffeine &gt; 5 units/day)&#xD;
&#xD;
          -  Subject who have drunken habitually (alcohol &gt; 21 units/week, 1 unit = pure alcohol&#xD;
             10ml)or who are unable to quit drinking during this study or smoker&#xD;
&#xD;
          -  positive for Hepatitis B, Hepatitis C, HIV or Syphilis&#xD;
&#xD;
          -  Blood Pressure is not in the range of &quot;140 &gt; sitting SBP ≥ 90mmHg, 90 &gt; sitting DBP ≥&#xD;
             60mmHg&quot;&#xD;
&#xD;
          -  Pulse rate is not in the range of &quot;95 &gt; sitting Pulse Rate ≥ 45bpm (beats per minute)&quot;&#xD;
&#xD;
          -  AST, ALT, total bilirubin over twice of reference range&#xD;
&#xD;
          -  Subjects deemed ineligible by investigator based on other reasons&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyun-Seop Bae, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <study_first_submitted>February 15, 2012</study_first_submitted>
  <study_first_submitted_qc>February 21, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2012</study_first_posted>
  <last_update_submitted>November 24, 2015</last_update_submitted>
  <last_update_submitted_qc>November 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine, Valsartan Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

